pksi-527 has been researched along with Disseminated-Intravascular-Coagulation* in 2 studies
2 other study(ies) available for pksi-527 and Disseminated-Intravascular-Coagulation
| Article | Year |
|---|---|
Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats.
The acute respiratory distress syndrome (ARDS) is a serious complication of sepsis. To evaluate the role of the coagulation system in the pathogenesis of ARDS in sepsis, we examined the effects of the administration of a synthetic plasma kallikrein specific inhibitor (PKSI) and of active-site blocked factor VIIa (DEGR-VIIa) on the pulmonary vascular injury induced by E. coli endotoxin (ET) in rats. Administration of PKSI prevented the pulmonary vascular injury induced by ET as well as pulmonary histological changes in animals administered ET, but it did not affect the intravascular coagulation. The opposite effect was seen with DEGR-VIIa, which prevented the intravascular coagulation but not the pulmonary vascular injury. PKSI did not inhibit the activation of the complement system induced by ET leading to the activation of neutrophils. Findings suggest that PKSI may prevent the pulmonary vascular injury induced by ET by inhibiting kallikrein, which activates the neutrophils. The intrinsic pathway of coagulation may be more important than the extrinsic pathway in the pulmonary vascular injury produced by ET. Topics: Amino Acid Chloromethyl Ketones; Animals; Binding Sites; Bronchoalveolar Lavage Fluid; Capillary Permeability; Dansyl Compounds; Disseminated Intravascular Coagulation; Endotoxemia; Endotoxins; Factor VIIa; Factor Xa Inhibitors; Kallikreins; Lung; Male; Phenylalanine; Pulmonary Artery; Pulmonary Veins; Rats; Rats, Wistar; Respiratory Distress Syndrome; Serine Proteinase Inhibitors; Specific Pathogen-Free Organisms; Tranexamic Acid | 1997 |
A finding of highly selective synthetic inhibitor of plasma kallikrein; its action to bradykinin generation, intrinsic coagulation and experimental DIC.
We found a novel and highly selective synthetic inhibitor of plasma kallikrein (PK), called PKSI-527; the Ki value was 0.81 microM. PKSI-527 inhibited the bradykinin (BK) generation induced by kaolin and prolonged partial thromboplastin time (PTT). PKSI-527 prevented the decrease of fibrinogen (Fg) levels due to i.v. injection of ellagic acid in mice and ameliorated the endotoxin (ET)-induced DIC in rats. Topics: Animals; Blood Coagulation; Bradykinin; Disease Models, Animal; Disseminated Intravascular Coagulation; Endotoxins; Fibrinogen; Humans; In Vitro Techniques; Kallikreins; Kaolin; Kinetics; Mice; Partial Thromboplastin Time; Phenylalanine; Rats; Tranexamic Acid | 1992 |